261 related articles for article (PubMed ID: 31050614)
1. Alemtuzumab Induction Is Associated With Equalization of Graft Outcomes Between Elderly and Nonelderly Kidney Transplant Recipients: A Single-Center Report.
DeLeonibus A; Mitro G; Brooks J; Rees M; Ortiz J
Exp Clin Transplant; 2020 Jun; 18(3):284-291. PubMed ID: 31050614
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab Induction Reduces Early Rejection in Female Renal Allograft Recipients: A Single Center Study.
Demeter J; Buck B; Zimmerman A; Mitro G; Rees M; Ortiz J
Exp Clin Transplant; 2019 Dec; 17(6):739-748. PubMed ID: 29633926
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab Induction Is Associated With an Equalization of Outcomes Between White and African American Kidney Transplant Recipients.
Brooks JT; Mitro G; DeLeonibus A; Qu W; Rees M; Nazzal M; Ortiz J
Exp Clin Transplant; 2019 Apr; 17(2):196-201. PubMed ID: 29206087
[TBL] [Abstract][Full Text] [Related]
4. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
[TBL] [Abstract][Full Text] [Related]
6. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.
Kim IK; Choi J; Vo AA; Kang A; Patel M; Toyoda M; Mirocha J; Kamil ES; Cohen JL; Louie S; Galera O; Jordan SC; Puliyanda DP
Transplantation; 2017 Apr; 101(4):883-889. PubMed ID: 27495773
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab Induction and Steroid Minimization in IgA Nephropathy: A Matched-Cohort Analysis.
Becker K; Brooks J; Mitro G; Rees M; Ortiz J
Exp Clin Transplant; 2020 Dec; 18(7):751-756. PubMed ID: 31875465
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab Induction Versus Conventional Immunosuppression in Heart Transplant Recipients.
Gale SE; Ravichandran B; Ton VK; Pham S; Reed BN
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):435-441. PubMed ID: 31035777
[TBL] [Abstract][Full Text] [Related]
11. Kidneys From Deceased Elderly Donors: Factors Associated With Adverse Outcomes.
Adekoya AO; Halawa A
Exp Clin Transplant; 2016 Feb; 14(1):32-7. PubMed ID: 26862822
[TBL] [Abstract][Full Text] [Related]
12. Does Induction Type Influence Outcomes in Kidney Transplant Recipients at Different Phases of Hepatitis B Infection?
Sureshkumar KK; Chopra B
Exp Clin Transplant; 2019 Aug; 17(4):457-460. PubMed ID: 30066624
[TBL] [Abstract][Full Text] [Related]
13. Elderly Kidney Transplant Recipients: Single-Center Experience in the Middle East.
Gheith O; Halim MA; Al-Otaibi T; El-Sayed A; Nair P; Mahmoud T; Fathy A; Hameed MA; Samy A; El Serwy N; Nagib AM
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):135-141. PubMed ID: 30777539
[TBL] [Abstract][Full Text] [Related]
14. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens.
Aydin-Ghormoz E; Ortiz J; Koizumi N; Li MH; Faddoul G
Pediatr Transplant; 2024 Jun; 28(4):e14783. PubMed ID: 38767019
[TBL] [Abstract][Full Text] [Related]
16. BK Virus in Renal Transplant Patients Using Alemtuzumab for Induction Immunosuppression.
Korneffel K; Gehring B; Rospert D; Rees M; Ortiz J
Exp Clin Transplant; 2020 Oct; 18(5):557-563. PubMed ID: 31324134
[TBL] [Abstract][Full Text] [Related]
17. Primary pediatric live-donor-kidney transplant-recipients' outcomes by immunosuppression induction received in the United States.
Riad S; Jackson S; Chinnakotla S; Verghese P
Pediatr Transplant; 2021 Aug; 25(5):e13925. PubMed ID: 33333629
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Alemtuzumab Versus Basiliximab Induction Therapy in Elderly Kidney Transplant Recipients: A Single-Center Experience.
Yakubu I; Ravichandran B; Sparkes T; Barth RN; Haririan A; Masters B
J Pharm Pract; 2021 Apr; 34(2):199-206. PubMed ID: 31315501
[TBL] [Abstract][Full Text] [Related]
19. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
Sampaio MS; Chopra B; Sureshkumar KK
Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563
[TBL] [Abstract][Full Text] [Related]
20. A study of the main determinants of kidney allograft long-term survival in the era of new immunosuppressive drugs.
Hekmat R; Sturdevant M
Saudi J Kidney Dis Transpl; 2019; 30(3):640-647. PubMed ID: 31249228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
